Investigational spleen tyrosine kinase (SYK) inhibitors for the treatment of autoimmune diseases
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Investigational spleen tyrosine kinase (SYK) inhibitors for the treatment of autoimmune diseases
Authors
Keywords
-
Journal
EXPERT OPINION ON INVESTIGATIONAL DRUGS
Volume -, Issue -, Pages 1-13
Publisher
Informa UK Limited
Online
2022-02-08
DOI
10.1080/13543784.2022.2040014
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- A Phase 1b, Randomized, Single-Center Trial of Topical Cerdulatinib (DMVT-502) in Patients with Mild-to-Moderate Atopic Dermatitis
- (2021) Stephen C. Piscitelli et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- Entospletinib and obinutuzumab in patients with relapsed/refractory chronic lymphocytic leukemia and B-cell malignancies
- (2021) Adam S. Kittai et al. HAEMATOLOGICA
- Gain-of-function variants in SYK cause immune dysregulation and systemic inflammation in humans and mice
- (2021) Lin Wang et al. NATURE GENETICS
- Spleen Tyrosine Kinase Inhibition Ameliorates Tubular Inflammation in IgA Nephropathy
- (2021) Wai Han Yiu et al. Frontiers in Physiology
- Constitutive JAK/STAT signaling is the primary mechanism of resistance to JAKi in TYK2-rearranged acute lymphoblastic leukemia
- (2021) Paniz Tavakoli Shirazi et al. CANCER LETTERS
- Spleen tyrosine kinase regulates crosstalk of hypoxia-inducible factor-1α and nuclear factor (erythroid-derived2)-like 2 for B cell survival
- (2021) Ju-Won Jang et al. INTERNATIONAL IMMUNOPHARMACOLOGY
- Efficacy of pharmacological treatment in rheumatoid arthritis: a systematic literature research informing the 2019 update of the EULAR recommendations for management of rheumatoid arthritis
- (2020) Andreas Kerschbaumer et al. ANNALS OF THE RHEUMATIC DISEASES
- Spleen tyrosine kinase inhibition is an effective treatment for established vasculitis in a pre-clinical model
- (2020) Stephen P. McAdoo et al. KIDNEY INTERNATIONAL
- Macrophage Syk–PI3Kγ Inhibits Antitumor Immunity: SRX3207, a Novel Dual Syk–PI3K Inhibitory Chemotype Relieves Tumor Immunosuppression
- (2020) Shweta Joshi et al. MOLECULAR CANCER THERAPEUTICS
- Piceatannol: A natural stilbene for the prevention and treatment of cancer
- (2020) Kishore Banik et al. PHARMACOLOGICAL RESEARCH
- Discovery of Lanraplenib (GS-9876): A Once-Daily Spleen Tyrosine Kinase Inhibitor for Autoimmune Diseases
- (2020) Peter Blomgren et al. ACS Medicinal Chemistry Letters
- Phase Ib Study of Tirabrutinib in Combination with Idelalisib or Entospletinib in Previously Treated Chronic Lymphocytic Leukemia
- (2020) Alexey V. Danilov et al. CLINICAL CANCER RESEARCH
- Pulmonary adverse events of small molecule JAK inhibitors in autoimmune disease: systematic review and meta-analysis
- (2020) Jun K Khoo et al. RHEUMATOLOGY
- Kinase inhibition in autoimmunity and inflammation
- (2020) Ali A. Zarrin et al. NATURE REVIEWS DRUG DISCOVERY
- Phase 1b study of tirabrutinib in combination with idelalisib or entospletinib in previously treated B-cell lymphoma
- (2020) Franck Morschhauser et al. LEUKEMIA
- Safety and efficacy of fostamatinib in rheumatoid arthritis patients with an inadequate response to methotrexate in phase II OSKIRA-ASIA-1 and OSKIRA-ASIA-1X study
- (2020) Yoshiya Tanaka et al. RHEUMATOLOGY
- Efficacy and Safety of Multiple Dosages of Fostamatinib in Adult Patients With Rheumatoid Arthritis: A Systematic Review and Meta-Analysis
- (2019) Yaqi Kang et al. Frontiers in Pharmacology
- Design and optimization of orally spleen tyrosine kinase (SYK) inhibitors for treatment of solid tumor
- (2019) Cheng Wang et al. BIOORGANIC CHEMISTRY
- Fostamatinib for the treatment of adult persistent and chronic immune thrombocytopenia: Results of two phase 3, randomized, placebo-controlled trials
- (2018) James Bussel et al. AMERICAN JOURNAL OF HEMATOLOGY
- Fostamatinib: First Global Approval
- (2018) Anthony Markham DRUGS
- Fostamatinib for persistent/chronic adult immune thrombocytopenia
- (2018) Adrian Newland et al. Immunotherapy
- Effects of GS-9876, a novel spleen tyrosine kinase inhibitor, on platelet function and systemic hemostasis
- (2018) Astrid S. Clarke et al. THROMBOSIS RESEARCH
- NF-κB activation mediates LPS- or zymosan-induced hypotension and inflammation reversed by BAY61-3606, a selective Syk inhibitor, in rat models of septic and non-septic shock
- (2018) Seyhan Sahan-Firat et al. CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY
- Cerdulatinib Pharmacodynamics and Relationships to Tumor Response Following Oral Dosing in Patients with Relapsed/Refractory B-cell Malignancies
- (2018) Greg P. Coffey et al. CLINICAL CANCER RESEARCH
- PMA inhibits endothelial cell migration through activating the PKC-δ/Syk/NF-κB-mediated up-regulation of Thy-1
- (2018) Heng-Ching Wen et al. Scientific Reports
- Inhibition of spleen tyrosine kinase attenuates psoriasis-like inflammation in mice through blockade of dendritic cell-Th17 inflammation axis
- (2018) Khalid S. Alzahrani et al. BIOMEDICINE & PHARMACOTHERAPY
- Syk inhibitors in clinical development for hematological malignancies
- (2017) Delong Liu et al. Journal of Hematology & Oncology
- Syk Regulates Neutrophilic Airway Hyper-Responsiveness in a Chronic Mouse Model of Allergic Airways Inflammation
- (2017) Sepehr Salehi et al. PLoS One
- BAY61-3606 potentiates the anti-tumor effects of TRAIL against colon cancer through up-regulating DR4 and down-regulating NF-κB
- (2016) Jipei Du et al. CANCER LETTERS
- The Dual Syk/JAK Inhibitor Cerdulatinib Antagonizes B-cell Receptor and Microenvironmental Signaling in Chronic Lymphocytic Leukemia
- (2016) Matthew D. Blunt et al. CLINICAL CANCER RESEARCH
- Pharmacokinetics, Pharmacodynamics, and Safety of Entospletinib, a Novel pSYK Inhibitor, Following Single and Multiple Oral Dosing in Healthy Volunteers
- (2016) Srini Ramanathan et al. CLINICAL DRUG INVESTIGATION
- Update on Lupus Nephritis
- (2016) Salem Almaani et al. Clinical Journal of the American Society of Nephrology
- PRT062607 Achieves Complete Inhibition of the Spleen Tyrosine Kinase at Tolerated Exposures Following Oral Dosing in Healthy Volunteers
- (2016) Greg Coffey et al. JOURNAL OF CLINICAL PHARMACOLOGY
- Inhibition of IKKα by BAY61-3606 Reveals IKKα-Dependent Histone H3 Phosphorylation in Human Cytomegalovirus Infected Cells
- (2016) Catherine M. K. Ho et al. PLoS One
- Fostamatinib, an oral spleen tyrosine kinase inhibitor, in the treatment of rheumatoid arthritis: a meta-analysis of randomized controlled trials
- (2016) Sumit Kunwar et al. RHEUMATOLOGY INTERNATIONAL
- Highly potent and selective pyrazolylpyrimidines as Syk kinase inhibitors
- (2015) Jang-Sik Choi et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- An open-label phase 2 trial of entospletinib (GS-9973), a selective spleen tyrosine kinase inhibitor, in chronic lymphocytic leukemia
- (2015) J. Sharman et al. BLOOD
- The Syk Inhibitor Fostamatinib Decreases the Severity of Colonic Mucosal Damage in a Rodent Model of Colitis
- (2015) Guray Can et al. Journal of Crohns & Colitis
- Human autoimmune diseases: a comprehensive update
- (2015) Lifeng Wang et al. JOURNAL OF INTERNAL MEDICINE
- Selective spleen tyrosine kinase inhibition delays autoimmune arthritis in mice
- (2015) ZUOFU ZHANG et al. Molecular Medicine Reports
- Simultaneous inhibition of JAK and SYK kinases ameliorates chronic and destructive arthritis in mice
- (2015) Alba Llop-Guevara et al. ARTHRITIS RESEARCH & THERAPY
- Pharmacokinetic-pharmacodynamic modeling of fostamatinib efficacy on ACR20 to support dose selection in patients with rheumatoid arthritis (RA)
- (2014) John Maringwa et al. JOURNAL OF CLINICAL PHARMACOLOGY
- Discovery of GS-9973, a Selective and Orally Efficacious Inhibitor of Spleen Tyrosine Kinase
- (2014) Kevin S. Currie et al. JOURNAL OF MEDICINAL CHEMISTRY
- A Phase III, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study of 2 Dosing Regimens of Fostamatinib in Patients with Rheumatoid Arthritis with an Inadequate Response to a Tumor Necrosis Factor- Antagonist
- (2014) M. C. Genovese et al. JOURNAL OF RHEUMATOLOGY
- Increased Syk phosphorylation leads to overexpression of TRAF6 in peripheral B cells of patients with systemic lupus erythematosus
- (2014) S Iwata et al. LUPUS
- Therapeutic Potential of Spleen Tyrosine Kinase Inhibition for Treating High-Risk Precursor B Cell Acute Lymphoblastic Leukemia
- (2014) T. Perova et al. Science Translational Medicine
- Getting Syk: spleen tyrosine kinase as a therapeutic target
- (2014) Robert L. Geahlen TRENDS IN PHARMACOLOGICAL SCIENCES
- Effects of Fostamatinib, an Oral Spleen Tyrosine Kinase Inhibitor, in Rheumatoid Arthritis Patients With an Inadequate Response to Methotrexate: Results From a Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study
- (2014) Michael E. Weinblatt et al. Arthritis & Rheumatology
- Safety profile of protein kinase inhibitors in rheumatoid arthritis: systematic review and meta-analysis
- (2013) Eva Salgado et al. ANNALS OF THE RHEUMATIC DISEASES
- Inhibition of spleen tyrosine kinase in the treatment of rheumatoid arthritis
- (2013) J. S. Nijjar et al. RHEUMATOLOGY
- Selective inhibition of spleen tyrosine kinase (SYK) with a novel orally bioavailable small molecule inhibitor, RO9021, impinges on various innate and adaptive immune responses: implications for SYK inhibitors in autoimmune disease therapy
- (2013) Cheng Liao et al. ARTHRITIS RESEARCH & THERAPY
- Tyrosine kinase inhibitors as potential drugs for B-cell lymphoid malignancies and autoimmune disorders
- (2012) Tadeusz Robak et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Inhibition of spleen tyrosine kinase as treatment of postoperative ileus
- (2012) Sjoerd H W van Bree et al. GUT
- Spleen Tyrosine Kinase Is Important in the Production of Proinflammatory Cytokines and Cell Proliferation in Human Mesangial Cells following Stimulation with IgA1 Isolated from IgA Nephropathy Patients
- (2012) M. J. Kim et al. JOURNAL OF IMMUNOLOGY
- Selective, novel spleen tyrosine kinase (Syk) inhibitors suppress chronic lymphocytic leukemia B-cell activation and migration
- (2012) J Hoellenriegel et al. LEUKEMIA
- Role of Spleen Tyrosine Kinase Inhibitors in the Management of Rheumatoid Arthritis
- (2011) David L. Scott DRUGS
- An oral Syk kinase inhibitor in the treatment of rheumatoid arthritis: A three-month randomized, placebo-controlled, phase II study in patients with active rheumatoid arthritis that did not respond to biologic agents
- (2010) Mark C. Genovese et al. ARTHRITIS AND RHEUMATISM
- The Syk inhibitor fostamatinib disodium (R788) inhibits tumor growth in the E - TCL1 transgenic mouse model of CLL by blocking antigen-dependent B-cell receptor signaling
- (2010) M. Suljagic et al. BLOOD
- Spleen tyrosine kinases: biology, therapeutic targets and drugs
- (2010) Mauro Riccaboni et al. DRUG DISCOVERY TODAY
- Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma
- (2010) R. Eric Davis et al. NATURE
- An Oral Spleen Tyrosine Kinase (Syk) Inhibitor for Rheumatoid Arthritis
- (2010) Michael E. Weinblatt et al. NEW ENGLAND JOURNAL OF MEDICINE
- Contribution of gut bacteria to the metabolism of the spleen tyrosine kinase (Syk) inhibitor R406 in cynomolgus monkey
- (2010) D. J. Sweeny et al. XENOBIOTICA
- Structural Insights for Design of Potent Spleen Tyrosine Kinase Inhibitors from Crystallographic Analysis of Three Inhibitor Complexes
- (2009) Armando G. Villaseñor et al. Chemical Biology & Drug Design
- Syk kinase inhibitors in allergic diseases
- (2009) J. Denyer et al. DRUG NEWS & PERSPECTIVES
- A novel Syk kinase inhibitor suitable for inhalation: R-343(?) – WO-2009031011
- (2009) Peter Norman EXPERT OPINION ON THERAPEUTIC PATENTS
- Treatment of rheumatoid arthritis with a syk kinase inhibitor: A twelve-week, randomized, placebo-controlled trial
- (2008) Michael E. Weinblatt et al. ARTHRITIS AND RHEUMATISM
- An orally bioavailable spleen tyrosine kinase inhibitor delays disease progression and prolongs survival in murine lupus
- (2008) Frances Rena Bahjat et al. ARTHRITIS AND RHEUMATISM
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now